Medical devices, healthcare technology and the business of care
PMA approval · P200029

TheraSphere

BOSTON SCIENTIFIC CORPORATION · Decision date Mar 17, 2021

MEDTECHLEDGER EXPLANATIONP200029

What did the FDA approve?

The FDA approved TheraSphere, a microspheres radionuclide device from Boston Scientific Corporation, on March 17, 2021. The approval covers selective internal radiation therapy for local tumor control of solitary tumors 1–8 cm in diameter in patients with unresectable hepatocellular carcinoma, Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.

The record does not identify a supplement type or reason, so this appears as an original PMA approval rather than a change to a prior system. The statement reports the device's indicated use; it does not independently establish safety or clinical effectiveness beyond that regulatory description.

FDA approval order statement

Approval for TheraSphereTM. This device is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.
Regulatory pathway
Original PMA
Clinical specialty
Radiology
Decision date
Mar 17, 2021

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200029
Regulatory pathway
Premarket approval application
Product code
NAW
Decision code
APPR
Decision date
Mar 17, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Microspheres radionuclide.

Product code
NAW
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200029 received

    Application receipt date recorded by FDA.

  2. P200029 · FDA decision

    APPR

  3. P200029/S015 · Related supplement

    TheraSphere Y-90 Glass Microspheres System

Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200029

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 13, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
300 Boston Scientific Way, Marborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records